Results 241 to 250 of about 161,388 (309)

The cerebral palsy directed acyclic graph: A structural causal model of aetiology

Developmental Medicine &Child Neurology, EarlyView.
The first international cerebral palsy directed acyclic graph (CP‐DAG) maps over 100 nodes and 370 links across biological, clinical, and social domains, offering a unified causal framework to guide research and identify knowledge gaps. Abstract Aim To describe the development of the initial version of the cerebral palsy (CP) directed acyclic graph ...
Shona Goldsmith, Sarah McIntyre, Nadia Badawi, Bernard Dan, Steven Day, Kate Himmelmann, Sandra Julsen Hollung, Bo Jacobsson, Gija Rackauskaite, Robert J. Reynolds   +9 more
wiley   +1 more source

Considerations for the clinical use of teplizumab in stage 2 Type 1 diabetes: A Consensus Statement from the British Society of Paediatric Endocrinology and Diabetes (BSPED) and the Association of British Clinical Diabetologists (ABCD)

Diabetic Medicine, EarlyView.
Abstract Introduction In 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) approved the use of teplizumab (a monoclonal anti‐CD3 antibody) to delay progression from Stage 2 to Stage 3 Type 1 diabetes in the UK. Methods To address the need for clear guidance on managing patients eligible for teplizumab therapy, the British Society of ...
Renuka P. Dias, M. Loredana Marcovecchio, Ruben H. Willemsen, Fiona Campbell, Ahmad Ashour, Philip Newland‐Jones, Jennifer Cooper, Parth Narendran, Neil P. Wright   +8 more
wiley   +1 more source

Development of Chimeric Antigen Receptor‐Modified NK Cells for the Immunotherapy of Adult T‐Cell Leukemia/Lymphoma

European Journal of Haematology, EarlyView.
ABSTRACT Adult T‐cell leukemia/lymphoma (ATL) is an aggressive hematological malignancy with a poor prognosis and limited therapeutic options. ATL cells exhibit aberrant surface glycosylation patterns resulting from dysregulated glycosyltransferase expression, representing a potentially tumor‐specific therapeutic target.
Yuichiro Uchida, Seigo Tateo, Masahiro Wakao, Hiroyuki Shinchi, Hayate Sawayama, Akira Fukumoto, Makoto Yoshimitsu, Yasuo Suda   +7 more
wiley   +1 more source

Disruption of iron metabolism resulting from Dmt1/Slc11a2 deficiency compromises Notch protein degradation and transcriptional activation

The FEBS Journal, EarlyView.
Divalent metal transporter 1 (Dmt1) maintains iron homeostasis and lysosomal proteostasis required for physiological Notch receptor–ligand signaling. Dmt1 loss lowers iron storage capacity (ferritin), increasing intracellular Fe2+, driving ROS and lipid peroxidation, and leading to lysosomal/mitochondrial dysfunction.
Rui Zhang, Somaieh Ahmadian, Jolanda Piepers, Florian Bock, Tom Keulers, Marc A. Vooijs   +5 more
wiley   +1 more source

Human Islet

Cell Proliferation, EarlyView.
Jiaqi Zou, Shen Li, Hongxing Fu, Mei Zhang, Anbin Hu, Xiaohui Tian, Yuanyuan Du, Lingling Wei, Xuchun Chen, Jie Gao, Rui Liang, Xinshun Feng, Yang Li, Ying Wang, Xiangheng Cai, Peng Sun, Xuejie Ding, Boya Zhang, Tengli Liu, Na Liu, Jie Hao, Lei Wang, Hongling Zhao, Jiani Cao, Aijin Ma, Lijun Zhu, Qiyuan Li, Qiang Wei, Xiaoming Ding, Ying Cheng, Tongbiao Zhao, Shusen Wang   +31 more
wiley   +1 more source

Biographical Feature: Thomas F. Smith, Ph.D. [PDF]

, 2017
Munson, Erik
core   +1 more source